Hadassah

Hadassah-Pluristem Trial Approved for Placental Cell Bone Marrow Regeneration

Monday, Feb 22 2016

The Federal Drug Administration (FDA) has approved the start of a Phase I trial with a placental-cell based therapy to mitigate acute radiation syndrome (ARS) and enhance bone marrow regeneration following a bone marrow transplant. The product, PLX-R18, was developed by Pluristem Therapeutics based on studies of Prof. Raphael Gorodetsky, head of Hadassah’s Biotechnology and Radiobiology Laboratories at the Sharett Institute of Oncology.

ARS (sometimes known as radiation toxicity or radiation sickness) is an acute lethal illness caused by irradiation of the entire body (or most of the body) by a high dose of penetrating radiation in a very short period of time. The syndrome affects the body’s ability to form new blood cells (hematopoietic recovery).

Prof. Gorodetsky and his colleagues helped Pluristem to identify the potency of the new cell product, having conducted an extensive preclinical study at Hadassah. The preclinical findings with PLX-R18 cells (also termed PLX-RAD) were initially published in PLOS-ONE (http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0066549) by Prof. Raphael Gorodetsky and the development team, and they were further verified at the National Institutes of Health (NIH) and other prominent centers in the United States. The new cell product’s mechanism of action was also explored in collaboration with the Charité Univeristy Medical Center in Berlin, where its researchers revealed that PLX-R18 cells secrete a wide range of specific proteins which could trigger the resurgence of the necessary early descendants of stem cells (progenitor cells) that can differentiate to form one or more kinds of cell and support the regeneration of all blood cell lineages.

The preclinical studies paved the way for PLX-R18’s application as a new treatment for cancer patients who suffer complications following high-dose radiation and chemotherapy. “PLX-R18-based therapy,” notes Prof. Gorodetsky, “may present a breakthrough in the lifesaving treatment of acute radiation syndrome, which so far has had very limited alternative treatments. It can be anticipated that this cell therapy may serve also as a safe and easy treatment for a variety of severe hematopoietic disorders.”

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Sep 23 2016

2016 Graduates from 19 Countries Celebrate Hadassah’s IMPH Program

Singing "It's a Wonderful Country" in Hebrew, wearing their native dress, the members of the 41st International Master of Public Health (IMPH) program of the Hadassah-Hebrew University Braun School of Public Health and Community Medicine celebrated their graduation.

READ MORE ›
alt_text

Monday, Sep 19 2016

Hadassah Hospital Treats Terror Victims After Stabbing Attacks

This last week has brought a burst of terror attacks.

READ MORE ›
alt_text

Thursday, Sep 15 2016

2012 Hadassah Stage-Four Melanoma Patient Thankfully Healthy

"Doctors in Florida who pronounced me ‘soon-dead’ can't believe that I'm healthy today,” said Hadassah melanoma patient Stewart Greenberg.

READ MORE ›
alt_text

Thursday, Sep 15 2016

“Stunning Results” Continue with Hadassah’s Stem Cell Treatment to Reverse MS

The Hadassah Medical Center is continuing to receive positive findings with its Phase II clinical trial using its unique stem cell approach to stop the progression and reversing the disabilities of multiple sclerosis.

READ MORE ›

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Membership Questions

membership@hadassah.org

(800) 664-5646

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Missions Department

missions@hadassah.org

(800) 237-1517

Show More